A moderately suspicious thyroid nodule is a lump whose ultrasound look puts it in the middle of the risk scale: not reassuring enough to ignore, but far from a cancer diagnosis. The estimated cancer risk is about 5 to 20 percent, so roughly 8 to 9 in 10 of these nodules are benign. Thyroid nodules are very common on neck scans, and most are harmless.1Elsevier / PubMed Central (Journal of the American College of Radiology). ACR Thyroid Imaging, Reporting and Data System (TI-RADS): White Paper of the ACR TI-RADS Committee The label works as an instruction to look closer, usually with a needle sample if the nodule is large enough or repeat scans if it is small. And even when a nodule in this range does prove to be cancer, it is most often a slow-growing type with an excellent outlook.
What Your Ultrasound Score Actually Says
Most reports in the US use TI-RADS, a scale from TR1 to TR5 that adds up points for how a nodule looks on ultrasound. A TR4 nodule is the “moderately suspicious” level, one step below the highest-concern group.2Thyroid Nodule Symptoms: TIRADS Scores and When to Act. Thyroid Nodule Symptoms: TIRADS Scores and When to Act
A TR4 nodule carries an estimated cancer risk of about 5 to 20 percent.3Thyroid Nodule Symptoms: TIRADS Scores and When to Act. Thyroid Nodule Symptoms: TIRADS Scores and When to Act The score describes how the nodule looks, not what its cells are, so only a biopsy or surgery can say for sure.
Points come from five things: what the nodule is made of, how bright or dark it looks, its shape, its edges, and any tiny bright spots. A solid, darker-than-normal nodule often lands in TR4 even with smooth edges. Features like being taller than wide or having irregular edges add more points and push toward TR5. Your report may list these words, and it is fair to ask your doctor which ones gave you the points.
The risk range is wide for the same reason. TR4 covers nodules from barely over TR3 to almost TR5, and where yours falls depends on its exact features. Two people both told “TR4” can have quite different individual odds.
TR1 and TR2 are considered benign and usually need nothing more. TR3 is mildly suspicious and only biopsied when quite large. TR5 is highly suspicious, with the highest risk on the scale. TR4 sits in between, which is why size matters so much for the next step.
Whether You Need a Biopsy or a Follow-Up Scan
Under American College of Radiology guidance, a TR4 nodule 1.5 cm or larger is usually biopsied. One from 1 to 1.5 cm is usually rechecked with ultrasound instead, often at 1, 2, 3 and 5 years. TR4 nodules under 1 cm generally need no follow-up from the score alone.
These cutoffs exist because small thyroid cancers are usually slow-growing, and finding and treating every tiny one has not been shown to help people live longer. Being told to wait is not the same as being ignored.
The biopsy is called fine-needle aspiration (FNA): a thin needle, guided by ultrasound, draws cells from the nodule. It is done in a clinic in about 20 to 30 minutes, usually with only local numbing or none.
On the day, you lie back with your neck stretched while the doctor finds the nodule on ultrasound. Several quick needle passes are taken, each lasting a few seconds. Mild soreness or a small bruise for a day or two is typical, and most people drive themselves home and go back to work the same day. Results usually take several days to a week or two.
If you are on a watch plan, the follow-up scans look for growth beyond a set amount or a change in features, either of which can prompt a biopsy. A nodule that stays stable over five years is reassuring. The main risk with watching is missing appointments, so put the dates on your calendar.
It helps to ask the nodule’s exact size and which features gave it its points, and why biopsy or monitoring was chosen in your case. Ask too whether a thyroid blood test has been done.
Reading Your Biopsy Result
Results fall into six Bethesda categories:
- Category I, nondiagnostic: not enough cells, usually repeated.
- Category II, benign: by far the most common result, seen in about 9 in 10 biopsies at one large center.4PubMed Central. The Bethesda system for reporting thyroid fine needle aspirates: A cytologic study with histologic follow-up
- Category III, AUS/FLUS: cells of unclear significance, an in-between result.5PubMed Central. Malignancy rates for Bethesda III and IV thyroid nodules: a retrospective study of the correlation between fine-needle aspiration cytology and histopathology
- Category IV, follicular neoplasm: a growth pattern a needle cannot fully judge.6PubMed Central. Malignancy rates for Bethesda III and IV thyroid nodules: a retrospective study of the correlation between fine-needle aspiration cytology and histopathology
- Category V, suspicious for cancer.
- Category VI, malignant: cancer cells were seen.
Unclear results are not rare. Among more than 11,000 biopsies, about 4 in 100 were Category III and about 7 in 100 Category IV.7PubMed Central. Malignancy rates for Bethesda III and IV thyroid nodules: a retrospective study of the correlation between fine-needle aspiration cytology and histopathology When a Category III nodule is biopsied again, about 4 in 10 repeats come back benign.8PubMed Central. Malignancy Rate in Thyroid Nodules Classified as Bethesda Category III (AUS/FLUS) But about 4 in 10 stay unclear, and fewer than 1 in 10 turn out suspicious or malignant.9PubMed Central. Malignancy Rate in Thyroid Nodules Classified as Bethesda Category III (AUS/FLUS)
An unclear result does not mean the lab found cancer. It means the cells looked unusual enough that the pathologist could not call them clearly normal. A follicular neoplasm describes a pattern of crowded cells that can be a harmless growth or a type of cancer.
A needle can’t always settle this because it sees loose cells, not how the growth sits in the surrounding tissue. Some types are defined by whether they break through their outer capsule, and that can only be seen after the whole nodule is removed.
What happens next depends on the result. Benign usually means occasional ultrasound checks, not surgery. Nondiagnostic means a repeat biopsy, usually after a short wait. Unclear results lead to a repeat biopsy, a gene test, or surgery. Suspicious or malignant results lead to a surgeon’s visit to plan treatment.
Gene Tests for an Unclear Biopsy
For an unclear result, the leftover sample can be sent for gene tests such as ThyroSeq or Afirma.10PubMed. Performance characteristics of ThyroSeq, ThyGeNEXT/ThyraMIR, and Afirma molecular platforms in evaluation of 1252 cytologically-indeterminate thyroid nodules Their main job is to identify nodules that are likely benign so surgery can be skipped.11PubMed Central. Thyroseq v3, Afirma GSC, and microRNA Panels Versus Previous Molecular Tests in the Preoperative Diagnosis of Indeterminate Thyroid Nodules: A Systematic Review and Meta-Analysis Newer versions like ThyroSeq v3 and Afirma GSC perform better than older ones.12PubMed Central. Thyroseq v3, Afirma GSC, and microRNA Panels Versus Previous Molecular Tests in the Preoperative Diagnosis of Indeterminate Thyroid Nodules: A Systematic Review and Meta-Analysis Still, in one large real-world group of over 1,200 unclear nodules, a negative result was right only about 7 or 8 times in 10.13PubMed. Performance characteristics of ThyroSeq, ThyGeNEXT/ThyraMIR, and Afirma molecular platforms in evaluation of 1252 cytologically-indeterminate thyroid nodules
The test uses cells from your biopsy, so you do not need a separate procedure if enough material was collected. Sometimes an extra needle pass is taken at the original biopsy and set aside for this purpose. The sample goes to a specialized lab, and results usually come back in about one to two weeks.
A negative result means the nodule is likely benign, and many people with it are monitored with ultrasound instead of having surgery. It lowers the chance of cancer but cannot reduce it to zero. So you would still be followed with scans, and any change in the nodule would be taken seriously.
Specific mutations carry different meanings. A BRAF V600E change found in a nodule nearly always means cancer.14PubMed. Fine-needle biopsy of thyroid nodules and the contribution of molecular analysis of BRAF and RAS mutations A RAS change is much less certain: of RAS-positive nodules removed at one center, about 6 in 10 were benign.15PubMed. Utilities of RAS Mutations in Preoperative Fine Needle Biopsies for Decision Making for Thyroid Nodule Management: Results from a Single-Center Prospective Cohort Cancers with only a RAS change were all low-risk with a good outlook.16PubMed. Utilities of RAS Mutations in Preoperative Fine Needle Biopsies for Decision Making for Thyroid Nodule Management: Results from a Single-Center Prospective Cohort A RAS result alone is therefore not a reason for alarm, but it is often a reason to discuss removing half the thyroid.
Coverage differs, and some public health systems do not pay for these tests. Health agencies disagree on whether they are worth the cost at current prices. It is worth asking before the biopsy whether extra sample can be saved for testing.
Without a gene test, removing one thyroid lobe is the usual way to get a firm answer. Many people keep normal thyroid function with one lobe left.
Personal Factors That Change Your Risk
Past radiation treatment roughly doubles thyroid cancer risk.17PubMed Central. Familial Risk Factors in Thyroid Cancer Across Generations and Geographics: A Systematic Review and Meta-Analysis Childhood radiation or chemotherapy each raises later risk, and together the risks add up.18PubMed Central. Radiation exposure and thyroid cancer: a review Children’s nodules are less common than adults’ but more often cancer.19PubMed Central. Evaluation of the efficacy of EU-TIRADS and ACR-TIRADS in risk stratification of pediatric patients with thyroid nodules Being overweight, smoking, and drinking did not clearly change risk.20PubMed Central. Familial Risk Factors in Thyroid Cancer Across Generations and Geographics: A Systematic Review and Meta-Analysis Thyroid nodules are found more often in women, but the share that prove to be cancer is not necessarily lower in men.
It helps to tell your doctor about any radiation to the head, neck or chest, especially in childhood, and about close relatives with thyroid cancer. These details can tip a borderline nodule toward biopsy.
Doctors usually check TSH (thyroid-stimulating hormone), the main blood test of thyroid function. Among people with normal thyroid function, a TSH in the upper-normal range, around 2.3 or above, came with roughly three times the cancer risk.21PubMed Central. Serum TSH levels as a predictor of malignancy in thyroid nodules: A prospective study Even so, it is only a nudge, not a test for cancer, since most people with higher values have benign nodules.
A calcitonin blood test checks for medullary cancer, a rare type. European doctors often test everyone; North American guidance generally does not. Ask about it if you have a family history of medullary cancer.
If It Is Cancer or Borderline
Some growths once called cancer are now named NIFTP, a borderline, non-cancer growth.22PubMed Central. The impact of non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) on the diagnosis of thyroid nodules They almost never spread; in one group followed for over 4 years none came back.23Journal of Surgery and Medicine. Reclassification as non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP): A retrospective review in a single institution and outcome study This change lowered the counted cancer risk for unclear biopsies.24PubMed. RISK OF MALIGNANCY IN THYROID CYTOLOGY: THE IMPACT OF THE RECLASSIFICATION OF NONINVASIVE FOLLICULAR THYROID NEOPLASM WITH PAPILLARY-LIKE NUCLEAR FEATURES (NIFTP) If it appears on your report, removal is usually all the treatment needed.
For suspicious biopsies without gene testing, removing one lobe is often offered to get a firm answer.25PubMed Central. Evaluation of a thyroid nodule Very small, low-risk cancers watched instead of removed rarely grew or spread among over 1,200 patients.26PubMed Central. Active surveillance for patients with very low‐risk thyroid cancer
The most common thyroid cancer, papillary, tends to grow slowly and is often confined to the thyroid when found. The long-term outlook for people treated for it is usually excellent. Being told you have cancer is frightening, but with this type it is usually the start of a planned treatment instead of an emergency.
Half removal often lets you skip daily thyroid pills, while whole removal means lifelong hormone pills. A rare risk of either is hoarseness from nerve injury. Your surgeon weighs tumor size and features.
After surgery, the removed tissue is examined, and the final report sometimes differs from the biopsy result. Based on that report, your team decides whether any further treatment is needed. For small, low-risk cancers removed with half the thyroid, follow-up is often just ultrasound and blood tests.
Large benign nodules can also press on the throat. Clinic-based heat or ablation treatments can shrink them by over half without surgery, but these are for confirmed benign nodules, not for suspicious ones awaiting answers.
Coping With the Wait
People with thyroid nodules report higher anxiety than those without.27PubMed Central. Exploring the psychological landscape of thyroid nodules: resilience, anxiety, and ultrasound correlations Nodules found by chance can also lead to unneeded tests, worry, and cost.28PubMed Central. Thyroid Ultrasonography: Much Ado About Nothing? A Provocative Analysis So asking whether each next test is truly needed is reasonable.
A few things make it more concrete. Write down your nodule’s score, size and next step. Remind yourself that most TR4 nodules are benign. Ask when and how you’ll get results so you’re not waiting on every phone call. And avoid comparing your case with online stories about other score levels. If you and your doctor choose monitoring, keep scheduled scans even when you feel fine.

